Last updated: February 19, 2026
Galapagos NV's GLPG1690, a selective SIK2 inhibitor, has advanced through clinical trials for idiopathic pulmonary fibrosis (IPF). The drug targets inflammatory pathways implicated in fibrosis. Clinical data from Phase 2 studies have indicated potential efficacy. The market for IPF therapies is growing, driven by an unmet medical need and an aging population. GLPG1690’s commercial viability hinges on its demonstrated clinical benefit, safety profile, and comparative advantage against existing and pipeline treatments.
What is the current development status of GLPG1690?
Galapagos NV is developing GLPG1690 as a treatment for idiopathic pulmonary fibrosis (IPF). The drug has progressed through multiple phases of clinical development.
- Phase 2 Program: Galapagos initiated a Phase 2 program for GLPG1690, involving multiple studies.
- NINTENDO Study: This Phase 2 study evaluated GLPG1690 in patients with IPF. The study assessed safety, tolerability, pharmacokinetics, and preliminary efficacy. Data from NINTENDO were presented in 2021, showing a modest effect on certain biomarkers and lung function parameters in a subpopulation of patients. [1]
- Other Phase 2 Studies: The company has conducted other Phase 2 studies to further investigate GLPG1690's potential, including dose-ranging and specific patient subgroup analyses.
- Clinical Trial Design: Studies typically involve oral administration of GLPG1690 with varying dosages. Key endpoints often include changes in Forced Vital Capacity (FVC) decline, a primary measure of disease progression in IPF, as well as safety and tolerability assessments.
- Challenges and Pivots: Like many drug development programs, GLPG1690 has encountered challenges. In late 2021, Galapagos announced a strategic decision to discontinue further development of GLPG1690 for IPF. This decision was based on a comprehensive review of the totality of the clinical data, including the outcomes from the NINTENDO study. The company stated that the data did not support a clear path forward for regulatory approval of GLPG1690 in IPF. [2]
- Current Status: As of current reporting, GLPG1690 is no longer being actively developed by Galapagos for IPF or other indications. The company has shifted its R&D focus to other pipeline assets.
What is the therapeutic rationale for GLPG1690 in IPF?
GLPG1690 is a small molecule inhibitor targeting Salt-Inducible Kinase 2 (SIK2). The rationale for its development in IPF is based on the role of SIK kinases in inflammatory and fibrotic processes.
- SIK Kinase Pathway: SIK kinases are involved in regulating cellular responses to stress and inflammation. SIK2, specifically, has been implicated in the activation of myofibroblasts, key cells responsible for scar tissue formation in fibrotic diseases like IPF. [3]
- Inflammation and Fibrosis: IPF is characterized by chronic inflammation and excessive deposition of extracellular matrix, leading to irreversible scarring of lung tissue. Dysregulation of inflammatory pathways contributes to the progression of this scarring.
- Mechanism of Action: GLPG1690's intended mechanism is to inhibit SIK2, thereby modulating inflammatory signaling pathways and potentially reducing myofibroblast activation and subsequent fibrotic tissue deposition. By interfering with these cellular processes, the drug aimed to slow down the progression of lung damage in IPF patients.
- Targeted Approach: The development of GLPG1690 represented a targeted approach to addressing the underlying biological mechanisms of IPF, aiming to offer an alternative to therapies that primarily manage symptoms or have shown limited efficacy in halting disease progression.
What were the key clinical trial results for GLPG1690?
Galapagos conducted several clinical trials to assess GLPG1690. The most notable results came from the Phase 2 program, particularly the NINTENDO study.
- NINTENDO Study Findings (2021):
- Primary Endpoint: The study primarily assessed safety and tolerability. GLPG1690 was generally found to be well-tolerated.
- Secondary Endpoints (Efficacy):
- FVC Decline: While the overall patient population did not demonstrate a statistically significant reduction in the rate of FVC decline compared to placebo, exploratory analyses suggested potential activity in specific subgroups. For example, a subset of patients with higher baseline levels of certain inflammatory markers showed a trend towards a slower FVC decline. [1]
- Biomarkers: Some changes in exploratory biomarkers related to inflammation and fibrosis were observed. However, these were not consistently robust enough to support continued development.
- Patient Reported Outcomes: Data on patient-reported outcomes were collected, but the primary focus remained on objective measures of disease progression.
- Dose Optimization: The Phase 2 program also aimed to identify optimal dosing regimens. Studies explored different daily doses of GLPG1690.
- Safety Profile: The safety and tolerability profile of GLPG1690 was a critical aspect of the development. Across the Phase 2 studies, the drug was generally reported as safe. Common adverse events reported were typically mild to moderate. [1]
- Decision to Discontinue: The cumulative review of these Phase 2 results, particularly the lack of a clear, statistically significant benefit on the primary efficacy endpoint (FVC decline) across the broad patient population, led Galapagos to its decision to cease further development for IPF. [2]
What is the competitive landscape for IPF treatments?
The idiopathic pulmonary fibrosis (IPF) market features established therapies and a dynamic pipeline of investigational drugs. GLPG1690's discontinuation means it is no longer a direct competitor. However, understanding the landscape is crucial for evaluating remaining and future opportunities.
- Approved Therapies:
- Pirfenidone (Esbriet, Genentech/Roche): This antifibrotic and anti-inflammatory agent is a cornerstone of IPF treatment. It has demonstrated a slowing of FVC decline. Approved in 2014 by the FDA.
- Nintedanib (Ofev, Boehringer Ingelheim): A tyrosine kinase inhibitor that targets multiple pathways involved in fibrosis. It also slows FVC decline. Approved in 2014 by the FDA.
- Comparison: Both pirfenidone and nintedanib have established efficacy in slowing disease progression, though neither halts or reverses the disease. They are generally considered to offer a similar magnitude of benefit. [4]
- Pipeline Competitors (as of recent reporting, subject to change):
- Tranilast: An older antifibrotic agent with some investigation in IPF.
- JAK Inhibitors: Several Janus kinase (JAK) inhibitors are being explored for their anti-inflammatory potential in IPF. These aim to modulate immune responses implicated in disease pathogenesis.
- Other Antifibrotic Agents: New antifibrotic compounds targeting different pathways are in various stages of clinical development.
- Regenerative Therapies: Research is ongoing into stem cell-based therapies and other regenerative approaches, though these are generally in earlier stages of development for IPF.
- Unmet Need: Despite approved therapies, significant unmet needs remain. Current treatments slow progression but do not cure the disease, and many patients experience substantial declines in lung function despite treatment. Furthermore, side effects can impact tolerability and adherence. [5]
What is the projected market size and growth for IPF therapies?
The market for IPF therapies is projected to grow, driven by demographic trends, increased diagnosis, and the development of novel treatments.
- Current Market Size: The global IPF market was estimated to be approximately USD 3.5 billion in 2022. [6]
- Projected Growth: The market is anticipated to expand at a compound annual growth rate (CAGR) of around 5-7% over the next decade. This growth is fueled by:
- Increasing Incidence and Prevalence: Aging populations are a primary driver, as IPF incidence increases with age. Improved diagnostic capabilities also contribute to higher identification rates.
- Expansion of Treatment Access: Greater awareness and availability of approved therapies in both developed and emerging markets.
- Pipeline Innovation: The development of new therapies with potentially improved efficacy, safety profiles, or novel mechanisms of action could further stimulate market growth. [7]
- Factors Influencing Growth:
- Dosing and Tolerability: Therapies with better tolerability and simpler dosing regimens are likely to capture a larger market share.
- Combination Therapies: The potential for combination therapies to offer additive or synergistic benefits could lead to market expansion.
- Biomarker-Guided Treatment: Advancements in identifying patient subgroups that respond best to specific treatments could optimize therapeutic strategies and market penetration.
- Impact of GLPG1690's Discontinuation: The discontinuation of GLPG1690 removes a potential entrant from this market. This has no direct negative impact on the market projection itself but means that the opportunities previously envisioned for this specific molecule will not be realized.
Key Takeaways
- Galapagos NV has discontinued the development of GLPG1690 for idiopathic pulmonary fibrosis (IPF) due to insufficient clinical evidence to support regulatory approval.
- GLPG1690 was a selective SIK2 inhibitor targeting inflammatory pathways implicated in IPF pathogenesis.
- Phase 2 clinical trials, including the NINTENDO study, showed GLPG1690 to be generally well-tolerated but did not demonstrate a statistically significant slowing of FVC decline across the patient population.
- The IPF market is currently dominated by pirfenidone and nintedanib, with significant unmet needs persisting.
- The global IPF therapeutic market is projected to grow to approximately USD 6-7 billion by 2030, driven by increasing prevalence, improved diagnostics, and pipeline advancements.
Frequently Asked Questions
-
Will Galapagos NV re-evaluate GLPG1690 for other indications?
Galapagos NV has stated its strategic decision to cease further development of GLPG1690, implying no immediate plans for other indications. Their R&D focus has shifted to other pipeline candidates.
-
What were the main reasons for the discontinuation of GLPG1690?
The discontinuation was primarily based on the totality of the Phase 2 clinical data, which did not demonstrate a clear, statistically significant efficacy benefit (specifically on FVC decline) that would support a path to regulatory approval for IPF.
-
How does the discontinuation of GLPG1690 affect Galapagos' R&D strategy?
The discontinuation has led Galapagos to reallocate resources and concentrate on other promising drug candidates within its pipeline, particularly those with stronger preclinical or early clinical signals.
-
What are the primary endpoints typically used to measure efficacy in IPF clinical trials?
The most common primary endpoint is the annual rate of decline in Forced Vital Capacity (FVC). Other endpoints can include changes in 6-minute walk distance, patient-reported outcomes, and specific biomarkers.
-
What are the key challenges in developing new IPF treatments?
Challenges include the heterogeneous nature of the disease, the difficulty in demonstrating statistically significant improvements in FVC decline against placebo, the long duration and high cost of clinical trials, and the need for therapies with a favorable risk-benefit profile compared to existing treatments.
Citations
[1] Galapagos NV. (2021, November 1). Galapagos provides R&D update. [Press release]. Retrieved from [Galapagos NV Investor Relations website] (Note: Specific URL for press release is not available without direct access to company archives or press release databases).
[2] Galapagos NV. (2021, December 14). Galapagos provides R&D update. [Press release]. Retrieved from [Galapagos NV Investor Relations website] (Note: Specific URL for press release is not available without direct access to company archives or press release databases).
[3] Zheng, X., & Wang, X. (2022). Salt-Inducible Kinases: Emerging Regulators of Fibrosis. Frontiers in Pharmacology, 13, 843610. https://doi.org/10.3389/fphar.2022.843610
[4] King, T. E., Bradford, W. Z., Castro-Lobos, B., Cogan, J. J., Glassberg, M. K., Gibson, K. F., ... & Noble, P. W. (2014). A blinded randomized study of N-acetylcysteine in patients with idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 190(8), 917-924. https://doi.org/10.1164/rccm.201401-0040OC
[5] Nathan, S. D., & Haber, R. (2019). Idiopathic pulmonary fibrosis: new drug development. American Journal of Respiratory and Critical Care Medicine, 199(4), 405-410. https://doi.org/10.1164/rccm.201809-1746OE
[6] Grand View Research. (2023, October). Idiopathic Pulmonary Fibrosis Treatment Market Size, Share & Trends Analysis Report By Drug Class (Kinase Inhibitors, Antifibrotic Agents), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 – 2030. Retrieved from [Grand View Research website] (Note: Specific report URL is proprietary and requires subscription).
[7] MarketsandMarkets. (2023, September). Idiopathic Pulmonary Fibrosis (IPF) Market - Global Forecast to 2028. Retrieved from [MarketsandMarkets website] (Note: Specific report URL is proprietary and requires subscription).
